Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis. Results from the HERCULES phase 3 study showed delay in disability ...

MG-ADL (Myasthenia Gravis - Activities of Daily Living) provides a rapid clinical assessment of the patient's recall of symptoms impacting activities of daily living, with a total score range of 0 to ...

Raymond James Financial Inc. purchased a new position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) in the fourth quarter, ...

Five-year-olds can be goofy. That was my first thought several years ago when my son stumbled and fell to the ground. But when he failed to get up and told ...

HighTower Advisors LLC raised its position in shares of KORU Medical Systems, Inc. (NASDAQ:KRMD – Free Report) by 13.0% during the fourth quarter, according to its most recent disclosure with the ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Immunovant, Inc.’s IMVT share price has dipped by 11.06%, which has investors questioning if this is right time to buy.

Jasmine McCabe-Gossett began noticing mild neuropathy in her hands and feet. It quickly progressed to “one of the most ...

Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

With these trends in view, let’s look at the 10 best mid cap biotech stocks to buy.

Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.